First Quadrant’s Albany Molecular Research Inc AMRI Stock Holding History

First Quadrant’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-23,600	Closed	-$443K	–	870
2016 Q4	$443K	Hold	23,600	–	–	0.01%	555
2016 Q3	$390K	Sell	23,600 -16,100	-41%	-$239K	0.01%	569
2016 Q2	$534K	Hold	39,700	–	–	0.01%	482
2016 Q1	$607K	Hold	39,700	–	–	0.01%	468
2015 Q4	$788K	Hold	39,700	–	–	0.02%	415
2015 Q3	$692K	Hold	39,700	–	–	0.02%	420
2015 Q2	$803K	Hold	39,700	–	–	0.02%	403
2015 Q1	$699K	Hold	39,700	–	–	0.01%	406
2014 Q4	$646K	Hold	39,700	–	–	0.01%	412
2014 Q3	$876K	Hold	39,700	–	–	0.02%	378
2014 Q2	$799K	Sell	39,700 -11,200	-22%	-$190K	0.02%	418
2014 Q1	$946K	Hold	50,900	–	–	0.02%	378
2013 Q4	$513K	Buy	50,900 +5,200	+11%	+$62.8K	0.01%	461
2013 Q3	$589K	Buy	+45,700	New	+$562K	0.01%	438

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

First Quadrant's AMRI Position: Q1 2017 in Review

First Quadrant sold out of Albany Molecular Research Inc (AMRI) in Q1 2017, closing a stake of 23,600 shares — an estimated $443K sold.

First Quadrant first reported a position in AMRI in Q3 2013 and held it in 14 quarters. The position peaked at $946K in Q1 2014. 139 funds tracked by Wall St. Rank hold AMRI as of Q1 2017.

First Quadrant reported no remaining Albany Molecular Research Inc position as of Q1 2017 after selling out during the quarter.
First Quadrant sold 23,600 Albany Molecular Research Inc shares in Q1 2017, an estimated $443K.
First Quadrant first reported a position in Albany Molecular Research Inc in Q3 2013 and held it in 14 quarters.
First Quadrant's Albany Molecular Research Inc position peaked at $946K in Q1 2014.
139 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2017.

Based on First Quadrant's 13F filing for Q1 2017, filed 25 Apr 2017.